Abstract PROteolysis TArgeting Chimeras (PROTACs) technology is a new protein-
degradation strategy that has emerged in recent years. It uses bifunctional small molecules …

Protease-targeted chimeras (PROTACs) are a new technology that is receiving much
attention in the treatment of diseases. The mechanism is to inhibit protein function by …

Proteolysis Targeting Chimeras (PROTACs), an emerging therapeutic entity designed to
degrade target proteins by hijacking the ubiquitin–proteasome system, have the potential to …

The technology known asPROTACs (PROteolysisTArgeting Chimeras) is a method of
protein degradation. Utilising bifunctional small molecules, the ubiquitin-proteosome system …

Abstract Cyclin-dependent kinase 2 (CDK2) is a potential therapeutic target for the treatment
of hearing loss and cancer. Previously, we identified AZD5438 and AT7519-7 as potent …

The success of inhibitor-based therapeutics is largely constrained by the acquisition of
therapeutic resistance, which is partially driven by the undruggable proteome. The …

Fundamental studies unraveled the role of eukaryotic initiation factor (eIF) 4E in mRNA
translation and its control. Under physiological conditions, regulation of translation by eIF4E …

Aberrant translation of proteins that promote cell proliferation is an essential factor that
defines oncogenic processes and cancer. The process for ribosomal translation of proteins …

Objective Aberrant activating mutations in cyclin-dependent kinases 4 and 6 (CDK4/6) are
common in various cancers, including gastroesophageal malignancies. Although CDK4/6 …

Eukaryotic initiation factor 4E (eIF4E) is a pivotal protein involved in the regulatory
mechanism for global protein synthesis in both physiological and pathological conditions …